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Abstract
We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as 
measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was 
conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant 
differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, 
based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding 
factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across vari-
ous health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and 
lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further 
research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.
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Introduction
Myelodysplastic syndromes (MDS) represent a heteroge-
neous group of hematologic malignancies characterized by 
peripheral cytopenia, ineffective hematopoiesis as mani-
fested by bone marrow cell dysplasia and risk for progres-
sion to acute myeloid leukemia [1].
Patients with MDS may develop iron overload, sec-
ondary to blood transfusions and increased intestinal iron 
absorption and altered distribution/retention (e.g., storing 
in macrophages) due to inadequate suppression of hepcidin 
that occurs as a consequence of ineffective erythropoiesis 
[2]. Accumulation of toxic iron species such as non-trans-
ferrin bound iron and labile plasma iron may also occur, 
resulting in increased levels of reactive oxygen species and 
subsequent tissue damage, with particular involvement of 
liver, heart and endocrine system [2, 3]. Recent insights 
have suggested that iron overload in MDS is not merely a 
secondary feature, but rather a systemic toxic disease [4].
Iron overload is typically monitored by serum ferritin 
(SF) concentration and, despite improved availability of 
advanced imaging techniques, SF remains the most com-
monly used approach to monitor iron overload and chela-
tion therapy. Serum ferritin measurements are inexpensive 
and generally correlate with both total body iron stores and 
clinical outcomes [5]. International guidelines recommend 
a ferritin-guided chelating approach (at least ≥ 1000 ng/
mL) for the treatment of iron overload in MDS patients 
[6].
Despite international MDS recommendations [6] 
emphasize the importance of health-related quality of life 
(HRQOL) as a key goal of therapy, little attention has 
historically been given to this aspect [7]. For example, 
while it is known that transfusion dependence and hyper-
ferritinemia are associated with adverse outcomes and 
shortened survival [8], there is dearth of information with 
regard to the association between hyperferritinemia, func-
tional status and symptom burden in MDS patients [9].
Therefore, we aimed to examine whether higher pre-
treatment SF concentration is associated with limitations 
in functional status or higher symptom severity in a large 
cohort of newly diagnosed MDS patients.
Materials and methods
Analysis was based on baseline data of an international 
observational study, which enrolled newly diagnosed 
adult patients with MDS between 2008 and 2018, across 
53 centers [10]. MDS diagnosis was performed by each 
Institute involved in the study. Out of the 647 patients for 
whom the SF value was included in case report forms (i.e., 
after protocol amendment in 2014), the SF data were avail-
able for 497 patients. This sample was split in two groups 
based on the SF value of 1000 ng/mL, with ≥ 1000 ng/mL 
indicating severe iron overload [6]. All patients completed 
the validated European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Core 
30 (EORTC QLQ-C30) [11]. This questionnaire includes 
five functional scales (i.e., physical, role, emotional, cog-
nitive, and social), three symptom scales (i.e., fatigue, 
nausea/ vomiting, and pain), six single-item scales (i.e., 
dyspnea, insomnia, appetite loss, constipation, diarrhea, 
and financial difficulties), and a global health status scale/
quality of life scale (GHS). However, for the purpose of 
this analysis, financial difficulties and the GHS scale were 
not considered. Clinically relevant differences of scales 
were evaluated and classified as small, medium and large, 
based on previously published thresholds [12].
The study was conducted in accordance with the Declara-
tion of Helsinki. All patients provided written informed con-
sent and the study was approved by the ethics committees of 
each participating center. We used proportions, medians and 
interquartile range (IQR) to describe the main characteristics 
and HRQOL profiles of MDS patients, overall and by SF 
levels (≥ 1000 ng/mL vs. < 1000 ng/mL). For exploratory 
purposes, additional cut-off values based on median (i.e., 
269 ng/mL) and 75th percentile (543 ng/mL) of SF levels 
in the overall population were also analyzed. We evaluated 
differences between groups of patients based on ferritin level 
by chi-square and Wilcoxon Mann–Whitney tests. Multi-
variable linear regression analysis was also performed to 
account for potential confounding factors. All tests were 
bilateral with statistical significance set as α = 0.05.
Results
Out of 497 patients with MDS analyzed, at ini-
tial diagnosis, 457 reported SF value < 1000  ng/mL 
(median = 240 ng/mL, IQR = 121–461), and 40 patients 
reported SF values ≥ 1000  ng/mL (median = 1477  ng/
mL; IQR = 1231–1989). The median age of patients was 
74 years (IQR = 67–80), and the majority of them were 
males (59.4%). Overall, the IPSS score was lower (i.e., low 
or intermediate-1) or higher (i.e., intermediate-2 or high) 
in 77.5% and 22.5% of patients, respectively. Patients with 
lower and higher SF level (i.e., < 1000 vs. ≥ 1000 ng/mL) 
were statistically significant different with respect to sex, 
ECOG performance status, number of comorbidities, hemo-
globin level and transfusion dependency. The distribution 
of patients according to the IPSS was similar in the two SF 
groups. Details are reported in (Table 1).
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Functional status and symptom profile
Small clinically relevant differences favoring patients with 
SF < 1000 ng/mL were found for the physical and emotional 
functioning scales (respectively, Δ =  − 9.7 points, p = 0.005 
and Δ =  − 10.3 points, p = 0.009). Figure 1 depicts mean 
scores differences of all functional scales of the EORTC 
QLQ-C30.
Patients with SF ≥ 1000 ng/mL reported statistically sig-
nificant and clinically relevant worse outcomes (i.e., higher 
scores) for the following symptoms: dyspnea, appetite 
loss, fatigue and pain. Dyspnea was the symptom indicat-
ing the largest difference and mean scores of patients with 
higher and lower SF levels were 40 and 24.3 respectively 
(p = 0.005), indicating a large clinically relevant difference 
(Δ = 15.7) (Fig. 1). Appetite loss reached a medium clini-
cally meaningful difference (Δ = 15.5), while differences for 
fatigue and pain were still of clinical relevance (Δ = 12.1 and 
Δ = 9.7, respectively), albeit of small magnitude (Fig. 1). 
Multivariable regression analysis controlling for sex, 
comorbidity, performance status, transfusion dependency 
and hemoglobin levels, showed that dyspnea, pain, appetite 
loss, and emotional functioning remained independently 
associated with SF levels. However, fatigue and physical 
functioning did not. Results of multivariate analysis of the 
above-reported symptoms are reported in Table 2.
Further investigation of other SF cut-off values as 269 ng/
mL (median) or 543 ng/mL (75 percentile) indicated no sig-
nificant differences in any of the considered EORTC QLQ-
C30 scales (data not shown).
Discussion
We observed that newly diagnosed MDS patients with 
higher SF levels reported clinically relevant impairments 
across various functional and symptom domains.
Ferritin is a known marker of inflammation, which has 
been shown to play a significant role in the pathogenesis 
of MDS [13], hence the increased inflammation status and 
the imbalances in cytokine levels may explain the greater 
symptom burden in patients with higher SF. The largest 
Table 1  Characteristics of 497 
patients with myelodysplastic 
syndromes by serum ferritin 
concentration
IQR interquartile range; IPSS international prognostic scoring system
a Transfusion dependency is defined as having received at least one red blood cell transfusion every 8 weeks 
over a period of 4 months
Variable Serum Ferritin, ng/mL
 < 1000 (N = 457)  ≥ 1000 (N = 40) Total (N = 497) p value
Age
 Median 73.8 75.6 73.8 0.688
 IQR 66.6–79.7 68.1–80.3 66.8–79.7
Sex, N (%)
 Male 265 (58.0) 30 (75.0) 295 (59.4) 0.036
 Female 192 (42.0) 10 (25.0) 202 (40.6)
ECOG performance status, N (%)
 0 209 (46.3) 11 (27.5) 220 (44.8) 0.022
  ≥ 1 242 (53.7) 29 (72.5) 271 (55.2)
 Missing 6 0 6
Comorbidity, N (%)
 0–1 317 (69.7) 17 (42.5) 334 (67.5)  < 0.001
  ≥ 2 138 (30.3) 23 (57.5) 161 (32.5)
 Missing 2 0 2
IPSS Risk groups, N (%)
 Low and Int.-1 356 (77.9) 29 (72.5) 385 (77.5) 0.433
 Int.-2 and High 101 (22.1) 11 (27.5) 112 (22.5)
Hemoglobin, g/dL
 Median 9.8 8.8 9.7  < 0.001
 IQR 8.7–11.4 7.9–9.6 8.6–11.3
Transfusion  dependencya, N (%)
 No 397 (87.6) 19 (48.7) 416 (84.5)  < 0.001
 Yes 56 (12.4) 20 (51.3) 76 (15.5)
 Missing 4 1 5
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Fig. 1  Functional status and symptom severity by baseline serum fer-
ritin concentration. The figure shows the mean scores for each scale 
of the EORTC QLQ-C30, by serum ferritin level. For functional 
scales, a higher score represents a higher level of functioning. For 
symptom scales, a higher score represents a higher symptom sever-
ity. For each scale, the corresponding Δ, represents the difference in 
mean scores between patients with serum ferritin level ≥ 1000 ng/mL 
and those with < 1000 ng/mL. *Indicates a small clinically meaning-
ful difference. **Indicates a medium clinically meaningful differ-
ence. ***Indicates a large clinically meaningful difference. Clinically 
important differences were only reported when differences were also 
statistically significant
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impairment (i.e., three times the magnitude of a minimal 
clinically important difference) was found for dyspnea in 
patients with iron overload compared with those with lower 
SF concentration. This association remained independent 
of other key potential confounding factors. Patients with 
chronic heart failure, a frequent complication in MDS 
patients, often suffer from dyspnea due to multifactorial 
mechanisms and, therefore, this finding begs for more 
research.
Along this line, the association we found between hyper-
ferritinemia and higher pain severity and appetite loss, which 
still remained independently associated with SF values, 
could also mirror the disease inflammatory burden. While 
pain is generally underestimated by physicians treating 
MDS patients, some recent studies have provided empirical 
evidence of the burden of this symptom both in lower [14] 
and higher risk MDS patients [15]. The interpretation of 
the association between higher fatigue and SF levels, is less 
clear as it was no longer independently associated with SF 
while accounting for confounding factors.
Our previous analysis, albeit conducted only in patients 
with higher risk disease, indicated that female gender, poor 
performance status and lower hemoglobin levels were inde-
pendently associated with higher fatigue severity, but SF 
was not considered [15]. It is possible to speculate that SF 
might be associated with specific HRQOL domains through 
different mechanisms of actions, that should be elucidated 
in future work.
Inspection of lower SF cut-off values (i.e., 269 and 
543 ng/mL) in our dataset, revealed no significant differ-
ences in any of the domains investigated. Using a higher SF 
threshold (i.e., 2000 ng/mL) than that used in our analysis, a 
previous study [9] did not find HRQOL differences between 
those with higher and lower SF values. However, that study 
[9] only included transfusion-dependent lower risk MDS 
patients with a median SF level of 2000 ng/mL, therefore, 
making it difficult a comparison with current findings.
Although the role of iron chelation in MDS patients is 
still a matter of debate, especially in those patients with 
an expected reduced survival (higher IPSS score), a recent 
study [16] has shown a general benefit of iron chelation 
on survival in lower risk IPSS patients, and this indication 
is included in international guidelines [6]. More than half 
of non-leukemic causes of death are due to cardiac failure 
secondary to iron overload [6]. However, a study on lower 
risk transfusion-dependent MDS patients treated with iron 
chelation therapy, showed no HRQOL benefits over a 1-year 
period [9]. In our sample, none of the patients with higher 
SF values received iron chelation therapy before HRQOL 
assessment. Future studies will have to identify specific sub-
groups of MDS patients for whom iron chelation therapy 
may be most beneficial.
In conclusion, our findings suggest to pay special atten-
tion to newly diagnosed MDS patients with high SF levels, 
as they may report clinically relevant impairments in some 
important symptoms. Further research is needed to better 
understand the relationship between SF levels and specific 
HRQOL domains.
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